ORTX - Orchard Therapeutics appoints Braden Parker as chief commercial officer

Orchard Therapeutics (ORTX) announces the appointment of healthcare and biotech industry veteran Braden Parker as its Chief Commercial Officer.Parker has 20 years of experience in the field and previously held positions at Celgene and PTC Therapeutics. He joined Orchard from PTC Therapeutics, where he served as vice president and general manager for the U.S. organization.Parker, who had been serving as Orchard’s senior vice president and general manager for North America, talked up a potential launch of its Libmeldy treatment in Europe. Libmeldy was approved in the EU in December 2020 as the first gene therapy for the treatment of early-onset metachromatic leukodystrophy, an inherited, neurodegenerative disorder.

For further details see:

Orchard Therapeutics appoints Braden Parker as chief commercial officer